Barclays PLC filed a Schedule 13G with the SEC on November 6, 2026, disclosing a beneficial ownership position in Aldeyra Therapeutics Inc as of September 30, 2026.

Key Highlights

  • Beneficial ownership: Barclays PLC reported aggregate beneficial ownership of 3,310,587 shares of Aldeyra Therapeutics common stock.
  • Percent of class: The 3,310,587 shares represent 5.48% of the class, according to the filing.
  • Sole voting and dispositive power: Barclays PLC reported sole voting power and sole dispositive power over all 3,310,587 shares, with zero shares subject to shared voting or shared dispositive power.
  • Triggering date: The event requiring the filing occurred on September 30, 2026.
  • Subsidiaries identified: The filing identifies Barclays Bank PLC, Barclays Capital Inc, and Barclays Capital Securities Ltd as the relevant subsidiaries through which the position is held.
  • Filer classification: Barclays PLC is identified as a parent holding company (type "HC") organized in the United Kingdom.

Barclays PLC Crosses 5% Threshold in Aldeyra Therapeutics Common Stock

Barclays PLC, a United Kingdom-incorporated parent holding company, submitted a Schedule 13G disclosing its beneficial ownership of common stock in Aldeyra Therapeutics Inc (NASDAQ:ALDX), whose principal executive offices are listed at 23 Bradford Street, MA, 02421. The filing was signed by Ramya Rao, Director, on November 6, 2026, with the triggering event dated September 30, 2026.

According to the filing, Barclays PLC beneficially owns 3,310,587 shares, equal to 5.48% of the class. The company reported sole voting power and sole dispositive power over all 3,310,587 shares. Shared voting power and shared dispositive power are each reported as zero. The filing names three subsidiaries through which the position is held: Barclays Bank PLC, Barclays Capital Inc, and Barclays Capital Securities Ltd.

The filing includes a certification stating that, to the best of the filer's knowledge and belief, "the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11."

What Was Disclosed

Barclays PLC disclosed a 5.48% beneficial ownership stake of 3,310,587 shares of Aldeyra Therapeutics common stock (CUSIP 01438T106) as of September 30, 2026, with sole voting and dispositive power over all reported shares, held through three named subsidiaries.